(-)-Terreic acid
(Synonyms: (-)-土曲霉酸) 目录号 : GC12164A selective inhibitor of BTK
Cas No.:121-40-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: about 100 μM for binding of GST-BtkPH to PKC, about 30 μM for association of Btk with PKCbII, about 10 μM for JNK1 activity, and about 7 μM for TNF-a and about 3 μM for IL-2.
Terreic acid (TA), which was known as Aspergillus sp. No. Y-8980, was isolated from a soil sample abtained at Yoron Island of Kagoshima Prefecture.
Terreic acid is a quinone epoxide with antibiotic activity. At a mechanism view for its antibiotic action, it inhibits protein synthesis by blocking the formation of leucyl-tRNA in sensitive bacteria [1]. TA was also an inhibitor of Bruton’s tyrosine kinase (Btk) that blocks the PKC-Btk PH domain interaction. Btk plays core roles in mast cell activation and in B cell development [2].
In vitro: Terreic acid showed MIC (minimal inhibitory concentration) of 25 approximately 100 mcg/ml, 50 mcg/ml and 12.5 mcg/ml against Gram-positive and Gram-negative bacteria, Xanthomonas citri and Xanthomonas oryzae and, respectively. TA also showed anti-tumor effect in the concentrations of > 6.25 mcg/ml on human carcinoma cells (HeLa cells) [1]. In lysates of HMC-1 human mast cells, TA can inhibit the binding of GST-BtkPH to PKC with an IC50 of ~100 uM. In mouse mast cells, TA can inhibit the association of Btk with PKCbII at IC50 of ~ 30 uM. JNK1 activity can be inhibited by TA with an IC50 of ~10 uM. Cytokine secretion was severely impaired by TA with an IC50 of ~7 uM for TNF-a and ~ 3 uM for IL-2) [2].
In vivo: In mice, the LD50 (median lethal dose) of TA was 75 mg/kg through i.p. and i.v. TA showed the enough survival effect in dd mice which have been implanted with Ehrlich ascites carcinoma cells, and the effect also was confirmed by anatomies of mice [1].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Yamamoto H, Moriyama K, Jinnouchi H, Yagishita K. Studies on terreic acid. Jpn J Antibiot. 1980 Mar;33(3):320-8.
[2] Kawakami Y, Hartman SE, Kinoshita E, Suzuki H, Kitaura J, Yao L, Inagaki N, Franco A, Hata D, Maeda-Yamamoto M, Fukamachi H, Nagai H, Kawakami T. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2227-32.
Cas No. | 121-40-4 | SDF | |
别名 | (-)-土曲霉酸 | ||
化学名 | (1S,6R)-3-hydroxy-4-methyl-7-oxabicyclo[4.1.0]hept-3-ene-2,5-dione | ||
Canonical SMILES | O=C(C(C)=C1O)[C@@H]2O[C@@H]2C1=O | ||
分子式 | C7H6O4 | 分子量 | 154.12 |
溶解度 | DMF: soluble,DMSO: 10 mg/ml,Ethanol: soluble,Methanol: soluble,Water: 5 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 6.4885 mL | 32.4423 mL | 64.8845 mL |
5 mM | 1.2977 mL | 6.4885 mL | 12.9769 mL |
10 mM | 0.6488 mL | 3.2442 mL | 6.4885 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。